Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial.

Published

Journal Article

AIMS: We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. METHODS AND RESULTS: The main efficacy endpoints were SSE and mortality; safety endpoints were major and major/clinically relevant non-major bleeding. A total of 4547/18 201 (24.9%) patients had diabetes who were younger (69 vs. 70 years), more had coronary artery disease (39 vs. 31%), and higher mean CHADS2 (2.9 vs. 1.9) and HAS-BLED scores (1.9 vs. 1.7) (all P < 0.0001) than patients without diabetes. Patients with diabetes receiving apixaban had lower rates of SSE [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.53-1.05), all-cause mortality (HR 0.83, 95% CI 0.67-1.02), cardiovascular mortality (HR 0.89, 95% CI 0.66-1.20), intra-cranial haemorrhage (HR 0.49, 95% CI 0.25-0.95), and a similar rate of myocardial infarction (HR 1.02, 95% CI 0.62-1.67) compared with warfarin. For major bleeding, a quantitative interaction was seen (P-interaction = 0.003) with a greater reduction in major bleeding in patients without diabetes even after multivariable adjustment. Other measures of bleeding showed a consistent reduction with apixaban compared with warfarin without a significant interaction based on diabetes status. CONCLUSION: Apixaban has similar benefits on reducing stroke, decreasing mortality, and causing less intra-cranial bleeding than warfarin in patients with and without diabetes.

Full Text

Duke Authors

Cited Authors

  • Ezekowitz, JA; Lewis, BS; Lopes, RD; Wojdyla, DM; McMurray, JJV; Hanna, M; Atar, D; Cecilia Bahit, M; Keltai, M; Lopez-Sendon, JL; Pais, P; Ruzyllo, W; Wallentin, L; Granger, CB; Alexander, JH

Published Date

  • April 2015

Published In

Volume / Issue

  • 1 / 2

Start / End Page

  • 86 - 94

PubMed ID

  • 27533976

Pubmed Central ID

  • 27533976

Electronic International Standard Serial Number (EISSN)

  • 2055-6845

Digital Object Identifier (DOI)

  • 10.1093/ehjcvp/pvu024

Language

  • eng

Conference Location

  • England